Skip to main content

Table 4 Risks of first drug prescription according to first level of Anatomical Therapeutic Chemical (ATC) Classification after date of diagnosis in CD subjects compared to matched references, stratified by first outcome occurrence (30–365 days after the index date/>365 days after the index date)a

From: Risks of hospitalization and drug consumption in children and young adults with diagnosed celiac disease and the role of maternal education: a population-based matched birth cohort study

First outcome occurrence

30–365 days

>1 year after index dateb

ATC codesb

REFERENCES

CD

HR (95 % CI)

REFERENCES

CD

HR (95 % CI)

n

py

n

py

n

py

n

py

A

131

5320

140

1129

4.70 (3.66–6.04)

406

32774

158

6926

1.78 (1.45–2.17)

B

48

5543

91

1534

6.35 (2.93–13.75)

210

34991

102

7669

2.36 (1.83–3.04)

C

18

5380

14

1222

3.53 (1.71–7.29)

84

35296

29

8289

1.42 (0.91–2.21)

D

43

5367

17

1220

1.45 (0.79–2.64)

137

34694

38

8162

1.14 (0.77–1.68)

G

22

5375

14

1221

2.38 (1.16–4.88)

104

35374

24

8408

0.97 (0.61–1.54)

H

209

5286

133

1157

3.07 (2.45–3.85)

569

32328

183

6925

1.65 (1.38–1.97)

J

1986

4300

524

941

1.27 (1.15–1.41)

1674

13312

361

2739

1.28 (1.10–1.49)

L

4

5386

12

1221

12.46 (3.94–39.42)

15

35964

13

8476

3.33 (1.52–7.29)

M

15

5383

14

1221

3.64 (1.66–7.97)

155

35291

59

8214

1.75 (1.27–2.41)

N

31

5368

16

1217

2.22 (1.20–4.12)

125

35335

40

8316

1.35 (0.93–1.97)

P

44

5368

30

1211

3.05 (1.88–4.94)

172

34891

60

8060

1.73 (1.27–2.35)

R

808

4969

248

1097

1.42 (1.23–1.65)

1251

22989

312

4907

1.26 (1.09–1.45)

S

43

5368

25

1217

2.29 (1.37–3.83)

104

34572

26

8035

1.03 (0.65–1.64)

  1. Py: person–years; CD: celiac disease; HR: Hazard Ratio; CI: confidence interval
  2. Figures in bold are statistically significant results (p-value <0.05)
  3. aMatched by year of birth, gender and maternal education; analysis restricted to subjects with index date ≥1995 (because drug prescription data are available from that year); bexcluding subjects with less than one year of follow-up for each outcome